HCMT/MM2401: Ph2 study of Selinexor + bispecific antibody for RRMM (Multiple Myeloma) - Clinical Trial
¿Cuál es el Propósito de este estudio?
The purpose of this study is to find out if combining a bispecific antibody with a drug called selinexor (XPOVIO) is a safe and effective option for multiple myeloma patients whose disease has returned after treatment or did not adequately respond to treatment.
Relapsed/Refractory Multiple Myeloma (RRMM)
¿Quién puede participar en el Estudio?
Adults ages 18+ who:
- Are diagnosed with multiple myeloma
- Have disease that returned after treatment or did not respond to treatment
For more information, contact the study team at kara.bonneau@duke.edu.
¿Qué Implica?
If you choose take part in this study, you will receive the study drug selinexor, along with bispecific antibodies that you would already be taking, for 12 months. Selinexor (XPOVIO) is approved by the U.S. Food and Drug Administration (FDA) for use in certain patients with RRMM, who have received at least 4 prior medications and whose disease is no longer responding to certain types of medication. As part of this study, you will have tests, exams, and procedures done as part of your normal care and for research.
Detalles del Estudio
